City of Hope

Ruchi Garg, MD, discusses several important ongoing studies of targeted therapies in patients with recurrent endometrial cancer.

In an interview with Targeted Oncology, Barbara Buttin, MD, discussed important ovarian cancer research for which results were presented during the 2023 ASCO Annual Meeting.

Sagun Shrestha, MD, discusses new trials that are exploring anti PD-1 therapy in the first-line setting for patients with small cell lung cancer.

In an interview with Targeted Oncology™, Patricia Rich, MD, discussed the data presented at ASCO 2023 and other recent trials that she found most exciting and important to the field of NSCLC treatment.

In an interview with Targeted Oncology, Sagun Shrestha, MD, evaluated new developments and clinical trials for patients with extensive-stage small cell lung cancer.

For Sarcoma Awareness Month, Lisa B. Ercolano, MD, and Mark Agulnik, MD, discussed the importance of understanding the genomics of sarcomas and how molecular testing can be useful in this space.

Sagun Shrestha, MD, discusses how the addition of atezolizumab and durvalumab to treatment options for patients with extensive stage small cell lung cancer has impacted the field for the better.

Ruchi Garg, MD, discusses the option of immunotherapy for the treatment of endometrial cancer.

The pan-tumor indication for immunotherapy in patients with mismatch repair deficient/microsatellite instability-high cancers has offered new treatment options and emphasized the importance of biomarker testing.

The National Comprehensive Cancer Network has updated its guidelines to include the recently approved T-cell engaging bispecific antibody epcoritamab for B-cell lymphomas.

In season 4, episode 8 of Targeted Talks, Ruchi Garg, MD, discusses treatment approaches for endometrial cancer now and in the near future.

In an interview with Targeted Oncology, Soyoung Park, MD, discusses the criteria used for determining transplant eligibility and choosing between the different types of transplants for patients with cancer.

Ruchi Garg, MD, discusses current treatment options and strategies being utilized for patients with endometrial cancer.

At the second planned interim analysis of the phase 3 SWOG S1826, the primary progression-free survival end point crossed the protocol-specified statistical boundary.

In an interview with Targeted Oncology, Narissa Nonzee, PhD, discussed a study which focused on increasing colorectal screening rates among patients in ethnic minority communities.

Tanya Dorff, MD, discusses the main findings from a phase 1 study of patients with metastatic castration-resistant prostate cancer.

Retrospective research suggests that low skeletal muscle mass at baseline may negatively impact outcomes in patients receiving chimeric antigen receptor T-cell therapy.

Oncologists are seeing early onset colorectal cancer more frequently, according to Jalal S. Baig, MD, medical oncologist at City of Hope Chicago.

In an interview with Targeted Oncology, Tycel Phillips, MD, discussed what led to the FDA approval of subcutaneous epcoritamab for patients with relapsed/refractory diffuse large B-cell lymphoma and how it adds to the current treatment landscape.

Tycel Phillips, MD, discusses the impact of the recent approval of subcutaneous epcoritamab for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma after 2 or more lines of systemic therapy.

Jeffrey R. Schriber, MD, FRCP, discusses some of the available treatment options for patients with multiple myeloma and how the treatment landscape has evolved over time.

In an interview with Targeted Oncology for World Ovarian Cancer Day, Natalie Godbee, DO, discussed the current state of treatment for advanced ovarian cancer and how oncologists can get the best outcomes for their patients.

Artificial intelligence and machine learning dramatically alter how medicine is practiced, and cancer detection is no exception, according to Toufic Kachaamy, MD of City of Hope Phoenix.

Branding move and leadership additions part of effort to deliver “one City of Hope” experience to patients across national clinical network.

In an interview with Targeted Oncology, Jeffrey R. Schriber, MD, discussed the impact of new advancements in the treatment of multiple myeloma, like the use of BiTE cells, on the current and future landscape for this patient population.

In season 3, episode 10 of Targeted Talks, Nitika Sharma, MD, discusses FDA-approved and promising novel therapies for the treatment of small cell lung cancer.

Ajaz M. Khan, MD, MBA, CPE, a medical oncologist and chair of the CTCA Department of Medical Oncology, explores available treatments for patients with well-differentiated neuroendocrine tumors.

New studies have shown promise for updated standards of care in patients with lymphoma.

In an interview with Targeted Oncology, Jeffrey R. Schriber, MD, reviews advances in leukemia treatment for Leukemia Awareness Month.

Although lung cancer screening rates are currently low, identifying the obstacles and potential solutions may raise the number of screenings in the United States.